**Shares of drugmaker Arcutis Biotherapeutics ARQT.O rise 12.9% to $16.91
** Co says it has agreed to temporarily pause a patent lawsuit with Israel-based Padagis regarding the latter attempting to produce a generic version of ARQT's Zoryve
** Zoryve is used to treat skin disorders including plaque psoriasis, seborrheic dermatitis and atopic dermatitis
** As part of the agreement, Padagis will keep Arcutis updated on any communication with the FDA about their generic version of Zoryve
** The patent for Zoryve is protected until at least 2037
** Including session's moves, ARQT stock up 19.4% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。